CureVac’s Nasdaq Era Concludes Following BioNTech Acquisition

CureVac NL0015436031

The independent public trading journey of CureVac has reached its conclusion. Following its acquisition by fellow German biotech firm BioNTech, CureVac's shares have been delisted from the Nasdaq exchange. Market attention now shifts to how BioNTech will advance the combined mRNA and oncology strategy.

BioNTech successfully completed its acquisition of CureVac in December 2025. The transaction was executed through a public exchange offer initiated the previous October. Subsequently, in January 2026, CureVac confirmed the completion of its corporate reorganization under the takeover terms, triggering the formal removal of its stock from the Nasdaq.

Key Developments at a Glance:

• Listing Status: CureVac's Nasdaq listing was terminated in January 2026.
• Transaction Close: BioNTech finalized the acquisition in December 2025.
• Strategic Focus: The combined entity prioritizes oncology and prophylactic vaccine development, alongside operational cost reductions.
• GSK Partnership: A previous collaboration with GSK on infectious diseases was converted into a licensing agreement.

Pipeline Progress Under New Ownership

Even as the merger proceeded, CureVac reported advancements in its clinical pipeline. These projects now transition to BioNTech's oversight. In September 2024, the company announced promising immune responses from a Phase 1 study of its CVGBM cancer vaccine candidate in patients with glioblastoma.

This was followed in April 2025 by the U.S. Food and Drug Administration (FDA) granting clearance for a Phase 1 trial of an mRNA-based immunotherapy for lung cancer. The integration and prioritization of these oncology and vaccine programs within BioNTech's broader development portfolio will be a critical focus moving forward.

Restructuring Paves the Way for Integration

Prior to the takeover, CureVac had already undertaken a significant strategic realignment. This involved transitioning its GSK partnership to a licensing model and sharpening its focus on oncology and preventive vaccines. Concurrent cost-cutting measures, including workforce reductions, were implemented to lower operational expenses.

This restructured foundation now provides the platform for BioNTech to integrate the acquired assets. The central question for investors and the industry is how BioNTech will leverage CureVac's technology and pipeline to strengthen its own position in the competitive mRNA therapeutics landscape.

@ boerse-global.de | NL0015436031 CUREVAC’S